AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Products

Products

Responding to global threats

AntoXa Corporation was created in response to growing demand for safe, effective therapeutics for national stockpiles against emerging threats to national security and public health, from weaponized chemical agents and pathogens.

Low-cost proprietary platform

AntoXa’s medical countermeasures are produced using a rapid, low-cost plant-based system that ensures high-quality drug products. With an exclusive license to use PlantForm Corporation’s vivoXPRESS® manufacturing system, AntoXa is able to produce a wide range of biopharmaceuticals in less than six weeks — far quicker than other systems.

A growing product pipeline

AntoXa Corporation is engaged with government and military agencies in Canada, the United States, Australia and Brazil to develop a range of biodefense solutions including:

PhD9 antibody for ricin exposure

AntoXa is developing a PhD9 antibody drug candidate under licence from Defence Research & Development (DRDC), using PlantForm’s vivoXPRESS® system to produce an antidote to ricin exposure. Ricin, a naturally occurring protein from the castor-bean plant, is extremely toxic to humans when inhaled or injected. PhD9 prevents ricin from penetrating cells.

Recombinant butyrylcholinesterase (rBuChE)

Butyrylcholinesterase (BuChE) is an enzyme that has been developed as a bioscavenger to provide prophylactic protection against nerve agents, such as sarin gas. AntoXa continues to advance the BuChE program begun by its parent company, PlantForm Corporation, under contract with Defence Research and Development Canada.

Hemopexin

Hemopexin is an innovative enzyme drug that shows promise for treating respiratory damage caused by sickle cell disease and exposure to toxic halogens such as chlorine gas. Research by the University of Alabama at Birmingham in collaboration with AntoXa scientists has demonstrated that recombinant human hemopexin, generated in plants using the vivoXPRESS® platform, was equally effective in reversing lung and mitochondrial injury caused by exposure to chlorine gas.

Latest News

AntoXa and SwiftPharma to present plant-made anti-ricin antibody technology to NATO expert panel

August 14, 2024

GUELPH, Ont., Canada, August 14, 2024 — AntoXa Corporation, a Canadian ...
Read more >

New Patent for AntoXa’s Plant-Made Anti-Ricin Antibody Manufacturing Process

January 30, 2024

GUELPH, Ont., Canada, January 30, 2024 — The Canadian Intellectual ...
Read more >

AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure

September 5, 2023

GHENT, Belgium and TORONTO, Canada, September 5, 2023 – AntoXa ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2025 · AntoXa Corporation | Site by Curry Gunn & Associates